| SCHEDULE OF EFFECTS OF THE RESTATEMENT TO AMOUNTS IN THE PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS |
The
following tables present the effects of the correction of the prior period error to the condensed consolidated statement of operations
and comprehensive loss (in thousands, except for per share data):
SCHEDULE
OF EFFECTS OF THE RESTATEMENT TO AMOUNTS IN THE PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS
| |
|
|
|
|
|
|
|
|
|
| |
|
For the three months ended March 31, 2022 |
|
| Condensed Consolidated Statement of Operations and Comprehensive Loss |
|
As Reported |
|
|
Adjustment |
|
|
As Revised |
|
| |
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
$ |
— |
|
|
$ |
(1,253 |
) |
|
$ |
(1,253 |
) |
| Net Loss |
|
$ |
(20,791 |
) |
|
$ |
(1,253 |
) |
|
$ |
(22,044 |
) |
| Basic and diluted loss per common share |
|
$ |
(3.59 |
) |
|
$ |
(0.21 |
) |
|
$ |
(3.80 |
) |
| Comprehensive loss |
|
$ |
(20,794 |
) |
|
$ |
(1,253 |
) |
|
$ |
(22,047 |
) |
The
following tables present the effects of the correction of the prior period error to the condensed consolidated cash flow statement (in
thousands):
| |
|
For the three months ended March 31, 2022 |
|
| Condensed Consolidated Cash Flow Statement |
|
As Reported |
|
|
Adjustment |
|
|
As Revised |
|
| |
|
|
|
|
|
|
|
|
|
| Net Loss |
|
$ |
(20,791 |
) |
|
$ |
(1,253 |
) |
|
$ |
(22,044 |
) |
| Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
$ |
— |
|
|
$ |
(1,253 |
) |
|
$ |
(1,253 |
) |
| Net cash provided by operating activities |
|
$ |
(13,687 |
) |
|
$ |
— |
|
|
$ |
(13,687 |
) |
The
following tables present the effects of the correction of the prior period error to the condensed consolidated statement of stockholders’
equity (in thousands):
| |
|
As of March 31, 2022 |
|
| Condensed Consolidated Statement of Stockholders’ Equity |
|
As Reported |
|
|
Adjustment |
|
|
As Revised |
|
| |
|
|
|
|
|
|
|
|
|
| Additional paid-in capital, December 31, 2021 |
|
$ |
705,570 |
|
|
$ |
(9,007 |
) |
|
$ |
696,563 |
|
| Total stockholders’ equity, December 31, 2021 |
|
$ |
51,375 |
|
|
$ |
(9,007 |
) |
|
$ |
42,368 |
|
| Net Loss |
|
$ |
(20,791 |
) |
|
$ |
(1,253 |
) |
|
$ |
(22,044 |
) |
| Additional paid-in capital, March 31, 2022 |
|
$ |
706,433 |
|
|
$ |
(9,007 |
) |
|
$ |
697,426 |
|
| Total stockholders’ equity, March 31, 2022 |
|
$ |
31,443 |
|
|
$ |
(10,260 |
) |
|
$ |
21,183 |
|
|
| SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE |
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
|
For the three months ended March 31, |
|
| |
|
2023 |
|
|
2022 |
|
| |
|
|
|
|
|
|
| Stock options |
|
|
234,697 |
|
|
|
284,072 |
|
| Restricted stock |
|
|
929,946 |
|
|
|
77,945 |
|
| Warrants |
|
|
9,397,879 |
|
|
|
1,788,000 |
|
| Total |
|
|
10,562,522 |
|
|
|
2,150,017 |
|
|